Characteristics of incident benzodiazepine recipients among US veterans with posttraumatic stress disorder.

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY American Journal of Health-System Pharmacy Pub Date : 2024-10-29 DOI:10.1093/ajhp/zxae311
Komel N Shahid, Katherine Hadlandsmyth, Delaney R Brainerd, Brian C Lund
{"title":"Characteristics of incident benzodiazepine recipients among US veterans with posttraumatic stress disorder.","authors":"Komel N Shahid, Katherine Hadlandsmyth, Delaney R Brainerd, Brian C Lund","doi":"10.1093/ajhp/zxae311","DOIUrl":null,"url":null,"abstract":"<p><strong>Disclaimer: </strong>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p><p><strong>Purpose: </strong>While benzodiazepine prescribing among veterans with posttraumatic stress disorder (PTSD) declined substantially in the Veterans Health Administration over the past decade, little is known about current incident prescribing. Our objective was therefore to describe patient, provider, facility, and prescribing characteristics among veterans with PTSD who were incident benzodiazepine recipients in 2022 and contrast these to the characteristics for incident recipients in 2012.</p><p><strong>Methods: </strong>This retrospective observational study included all veterans with PTSD who received an incident benzodiazepine prescription during calendar year 2022 and separately for 2012. The distribution of patient, provider, facility, and benzodiazepine prescribing characteristics was contrasted between years. Stratified subanalyses were conducted by potential non-PTSD benzodiazepine indication, including anxiety and sleep disorders.</p><p><strong>Results: </strong>A total of 28,310 (6.6%) incident benzodiazepine recipients were identified in 2012, which decreased to 16,776 (1.9%) incident recipients in 2022. The proportion of initial prescriptions written for a days' supply of 30 or more days decreased from 75.6% to 51.7%, and the proportion who received a second prescription within 6 months decreased from 68.7% to 53.5%. The proportion of patients with diagnoses for potential benzodiazepine indications also increased, including for generalized anxiety disorder (15.1% increase), obsessive compulsive disorders (0.6% increase), panic disorder (6.7% increase), and sleep disorders (22.9% increase).</p><p><strong>Conclusion: </strong>As incident benzodiazepine prescribing among veterans with PTSD decreased over the past decade, so did the volume of drug dispensed and duration of therapy, while the prevalence of documented prescriptions for non-PTSD indications increased.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxae311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Purpose: While benzodiazepine prescribing among veterans with posttraumatic stress disorder (PTSD) declined substantially in the Veterans Health Administration over the past decade, little is known about current incident prescribing. Our objective was therefore to describe patient, provider, facility, and prescribing characteristics among veterans with PTSD who were incident benzodiazepine recipients in 2022 and contrast these to the characteristics for incident recipients in 2012.

Methods: This retrospective observational study included all veterans with PTSD who received an incident benzodiazepine prescription during calendar year 2022 and separately for 2012. The distribution of patient, provider, facility, and benzodiazepine prescribing characteristics was contrasted between years. Stratified subanalyses were conducted by potential non-PTSD benzodiazepine indication, including anxiety and sleep disorders.

Results: A total of 28,310 (6.6%) incident benzodiazepine recipients were identified in 2012, which decreased to 16,776 (1.9%) incident recipients in 2022. The proportion of initial prescriptions written for a days' supply of 30 or more days decreased from 75.6% to 51.7%, and the proportion who received a second prescription within 6 months decreased from 68.7% to 53.5%. The proportion of patients with diagnoses for potential benzodiazepine indications also increased, including for generalized anxiety disorder (15.1% increase), obsessive compulsive disorders (0.6% increase), panic disorder (6.7% increase), and sleep disorders (22.9% increase).

Conclusion: As incident benzodiazepine prescribing among veterans with PTSD decreased over the past decade, so did the volume of drug dispensed and duration of therapy, while the prevalence of documented prescriptions for non-PTSD indications increased.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
患有创伤后应激障碍的美国退伍军人中服用苯二氮卓类药物者的特征。
免责声明:为了加快文章的发表,AJHP在接受稿件后会尽快将其发布到网上。被录用的稿件已经过同行评审和校对,但在进行技术格式化和作者校对之前会在网上发布。目的:过去十年中,退伍军人健康管理局对患有创伤后应激障碍(PTSD)的退伍军人开具的苯二氮卓类药物处方大幅减少,但对目前的处方情况却知之甚少。因此,我们的目标是描述 2022 年患有创伤后应激障碍的退伍军人中服用苯二氮卓类药物的患者、提供者、设施和处方特征,并将这些特征与 2012 年服用苯二氮卓类药物的退伍军人的特征进行对比:这项回顾性观察研究包括所有在 2022 历年期间接受过苯二氮卓类药物处方的创伤后应激障碍退伍军人,2012 年的情况也是如此。对不同年份的患者、医疗服务提供者、医疗机构和苯二氮杂卓处方的分布特征进行了对比。按苯二氮卓类药物的潜在非创伤后精神紧张症适应症(包括焦虑症和睡眠障碍)进行了分层子分析:2012年共发现28,310例(6.6%)苯二氮卓类药物事件接受者,2022年降至16,776例(1.9%)。首次开具 30 天或 30 天以上用量处方的比例从 75.6% 降至 51.7%,6 个月内第二次开具处方的比例从 68.7% 降至 53.5%。被诊断为苯二氮卓类药物潜在适应症的患者比例也有所增加,包括广泛性焦虑症(增加 15.1%)、强迫症(增加 0.6%)、恐慌症(增加 6.7%)和睡眠障碍(增加 22.9%):结论:在过去十年中,患有创伤后应激障碍的退伍军人服用苯二氮卓类药物的情况有所减少,配药量和治疗时间也有所缩短,而有记录的非创伤后应激障碍适应症处方的流行率却有所上升。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.90
自引率
18.50%
发文量
341
审稿时长
3-8 weeks
期刊介绍: The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.
期刊最新文献
Analysis of 10-year income trends for pharmacists and other select health professionals. Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder. Success of an expedited health system-based pharmacy technician training program to address the workforce needs of an institution. Understanding individual experiences with stick-built and modular cleanrooms: Lessons learned and a call to action. A pilot project implementing a team-based approach for remote physiologic monitoring in an accountable care organization.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1